Skip to content
All resources

MOTS-c

Mitochondrial Peptides in 2027: MOTS-c, SS-31 and the Future of Cellular Energy

JH

By

· 5 min read

A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.

On this page · 7 sections
  1. MOTS-c: mitochondria as signalling systems
  2. SS-31: a different mitochondrial strategy
  3. A significant regulatory milestone
  4. Why mitochondrial research matters for ageing biology
  5. What could happen in 2027?
  6. Looking forward
  7. Further reading

Mitochondria have long been described as the powerhouses of the cell. Their role in energy production is essential, but research has shown that these organelles also take part in cellular stress responses, metabolic adaptation and communication between different parts of the cell.

That has created interest in mitochondrial peptides. Two of the most widely discussed are MOTS-c and SS-31. Both are associated with mitochondrial biology, but they work through different proposed mechanisms and have reached very different stages of clinical development.

A cut-away mitochondrion with teal folded membranes, small glowing particles travelling from it toward a cell nucleus
Illustration: mitochondria as signalling organelles, not only energy producers.

MOTS-c: mitochondria as signalling systems

MOTS-c is a short peptide encoded within mitochondrial DNA. Its discovery contributed to a broader view of mitochondria as sources of biologically active signalling molecules, and experimental research has examined it in relation to cellular responses to metabolic stress.

One focus is AMPK-associated pathways, which help maintain cellular energy balance. Other studies have explored its relationship with cellular adaptation, gene expression and metabolic regulation. Much of this work comes from laboratory and animal models. A 2026 systematic review of mitochondrial-derived peptides and exercise found nine eligible studies, most reporting a trend toward higher levels after exercise, and cautioned that the human evidence is limited (Ayubi and colleagues, 2026). Robust clinical evidence for any effect of externally administered MOTS-c in people does not exist. Background is in what MOTS-c is.

SS-31: a different mitochondrial strategy

SS-31, also known as elamipretide, is a synthetic peptide associated with mitochondrial membrane biology. Its proposed mechanism centres on cardiolipin, a phospholipid found predominantly in the inner mitochondrial membrane, which helps organize and stabilize the protein complexes of mitochondrial energy production. That is fundamentally different from the signalling biology associated with MOTS-c. The lipid is covered in cardiolipin explained.

A significant regulatory milestone

On September 19, 2025, the US Food and Drug Administration granted accelerated approval to elamipretide, as Forzinity, for improving muscle strength in patients with Barth syndrome weighing at least 30 kilograms (Zhao and colleagues, 2025). Barth syndrome is a rare inherited disorder in which cardiolipin remodelling, and with it mitochondrial function, is impaired.

That established a regulated therapeutic use for a mitochondria-targeted peptide. But accelerated approval carries evidentiary and post-approval requirements, including a confirmatory trial, and the authorized indication is narrow. In the randomized crossover trial, elamipretide did not significantly improve the six-minute walk test or fatigue scores; the reported benefits came from a long open-label extension. The approval does not show that SS-31 improves energy, athletic performance or longevity in general, and research-grade SS-31 should not be assumed equivalent to the authorized drug product. It is also not a Canadian authorization. More is in what SS-31 is.

MOTS-cSS-31 (elamipretide)
OriginEncoded in mitochondrial DNASynthetic, designed
Proposed focusMetabolic and stress signallingInner-membrane cardiolipin
Evidence stageMostly cell and animal workDisease-specific clinical trials
Regulatory statusInvestigationalUS accelerated approval for Barth syndrome only

Why mitochondrial research matters for ageing biology

Ageing is associated with changes in mitochondrial activity, cellular stress responses and metabolic regulation, and researchers are investigating how these interact with inflammation, tissue function and age-related disease.

MOTS-c gives researchers a way to examine mitochondria-derived signalling; SS-31 illustrates an approach aimed at mitochondrial membrane biology. Neither mechanism establishes an anti-ageing benefit. Such a claim would need controlled human studies measuring clinically relevant outcomes. A side-by-side comparison is in MOTS-c vs SS-31.

What could happen in 2027?

Continued study of elamipretide, including its confirmatory trial, may clarify the clinical relevance of cardiolipin-directed approaches. Researchers may better understand how mitochondrial-derived peptides take part in cellular communication, and better analytical methods could help distinguish naturally produced signalling peptides from synthetic compounds designed to act on mitochondria.

More rigorous clinical research may then show which proposed applications deserve further development.

Mitochondrial peptide science is moving beyond the idea that mitochondria simply produce energy. The more interesting question is how these organelles communicate with the rest of the cell.

Looking forward

Mitochondrial research remains one of the most interesting areas of peptide biology. The next step is finding out whether molecular discoveries translate into reproducible clinical findings. In 2027, progress will be measured not only by what happens inside cells, but by what scientists can reliably demonstrate in human studies.

Supplied here for laboratory use: MOTS-c and SS-31. For laboratory research use only.

Experimental findings do not establish clinical effects or general longevity benefits. Nothing here is medical, dosing or therapeutic guidance.

Selected Research References

  1. Zhao C, Zhuang X, Gao J. Elamipretide: The first cardiolipin-directed mitochondrial therapeutic for Barth syndrome approved under accelerated approval. Drug Discoveries & Therapeutics. 2025;19(6):435-436. pubmed.ncbi.nlm.nih.gov/41260682
  2. Ayubi N, Wibawa JC, Kurnaz M, Komaini A. Mitochondrial-derived peptides (MDPs) activated by physical exercise as therapeutic targets for metabolic disorders: A systematic review. Physiology International. 2026;113(3):327-349. pubmed.ncbi.nlm.nih.gov/42640735

Further reading

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.